Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|October 2, 2024

Navigating Toxicity: Comparing Third-Line mCRC Therapies

Author(s)Ryan Haumschild, PharmD, MS, MBA, Marwan Fakih, MD , Michael Morse, MD, MHS, FACP

Medical experts compare the toxicity profiles of FTD/TPI plus bevacizumab, regorafenib, and fruquintinib, and discuss practical strategies for managing treatment-related toxicities with these third-line therapies.

Episodes in this series

EP. 1 Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC

EP. 1 Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC

EP. 2 Real-World Impact of SUNLIGHT Outcomes in mCRC

EP. 2 Real-World Impact of SUNLIGHT Outcomes in mCRC

EP. 3 Fruquintinib in mCRC: Key Insights From FRESCO-2

EP. 3 Fruquintinib in mCRC: Key Insights From FRESCO-2

EP. 4 Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib

EP. 4 Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib

EP. 5 Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions

EP. 5 Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions

EP. 6 Guiding Patients Through Third-Line mCRC Therapy Decisions

EP. 6 Guiding Patients Through Third-Line mCRC Therapy Decisions

EP. 7 Navigating Toxicity: Comparing Third-Line mCRC Therapies

EP. 7 Navigating Toxicity: Comparing Third-Line mCRC Therapies

EP. 8 Evaluating Quality of Life and Adherence With mCRC Treatment Options

EP. 8 Evaluating Quality of Life and Adherence With mCRC Treatment Options

EP. 9 Integrating Support Services and Caregiver Roles in mCRC Care

EP. 9 Integrating Support Services and Caregiver Roles in mCRC Care

EP. 10 mCRC Treatment Access: IRA Cost Cap Impact and Final Insights

EP. 10 mCRC Treatment Access: IRA Cost Cap Impact and Final Insights

Video content above is prompted by the following:

How do the toxicity profiles differ with FTD/TPI plus bevacizumab, as compared with regorafenib or fruquintinib, and how might these different toxicity profiles be leveraged when making treatment selections?
What are some key, practical strategies you use to manage treatment-related toxicities with these third-line therapies?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

AJMC original research clinical

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Experts featured in this series.

Contextualizing Golcadomide's Efficacy Signal in the RRFL Landscape

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Christina Poh, MD,Tara Graff DO, MS

July 23rd 2026

Experts featured in this series.

The Role of Radiotherapy in Advanced Follicular Lymphoma

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Christina Poh, MD,Tara Graff DO, MS

July 23rd 2026

Man having heart attack - dragonstock - stock.adobe.com

Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial

ByPearl Steinzor

July 22nd 2026

David Zhang

Challenges to Clinical Implementation of IPF Polygenic Risk Scores: David Zhang, MD

BySabrina McCrear,David Zhang, MD

July 22nd 2026

Trending on AJMC

Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029

Fifth Death Confirmed in NYC Legionnaires' Outbreak

Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial

Contextualizing Golcadomide's Efficacy Signal in the RRFL Landscape

The Role of Radiotherapy in Advanced Follicular Lymphoma